These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 27855197)

  • 41. Investigational VEGF antagonists for psoriasis.
    Crawshaw AA; Griffiths CE; Young HS
    Expert Opin Investig Drugs; 2012 Jan; 21(1):33-43. PubMed ID: 22088218
    [TBL] [Abstract][Full Text] [Related]  

  • 42. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
    Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials.
    Qi WX; Shen Z; Tang LN; Yao Y
    Br J Clin Pharmacol; 2014 Oct; 78(4):748-62. PubMed ID: 24661224
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding.
    Graziani G; Ruffini F; Tentori L; Scimeca M; Dorio AS; Atzori MG; Failla CM; Morea V; Bonanno E; D'Atri S; Lacal PM
    Oncotarget; 2016 Nov; 7(45):72868-72885. PubMed ID: 27655684
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction.
    Ko HT; Yin JL; Wyburn K; Wu H; Eris JM; Hambly BD; Chadban SJ
    Nephrol Dial Transplant; 2013 Feb; 28(2):327-36. PubMed ID: 23229928
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vascular endothelial growth factors and receptors are up-regulated during development of apical periodontitis.
    Bletsa A; Virtej A; Berggreen E
    J Endod; 2012 May; 38(5):628-35. PubMed ID: 22515891
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
    Chung AS; Kowanetz M; Wu X; Zhuang G; Ngu H; Finkle D; Komuves L; Peale F; Ferrara N
    J Pathol; 2012 Aug; 227(4):404-16. PubMed ID: 22611017
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Granulocyte-Colony Stimulating Factor Receptor, Tissue Factor, and VEGF-R Bound VEGF in Human Breast Cancer In Loco.
    Wojtukiewicz MZ; Sierko E; Skalij P; Kamińska M; Zimnoch L; Brekken RA; Thorpe PE
    Adv Clin Exp Med; 2016; 25(3):505-11. PubMed ID: 27629739
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epigallocatechin-3-gallate inhibits estrogen-induced activation of endometrial cells in vitro and causes regression of endometriotic lesions in vivo.
    Laschke MW; Schwender C; Scheuer C; Vollmar B; Menger MD
    Hum Reprod; 2008 Oct; 23(10):2308-18. PubMed ID: 18603648
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis.
    Ba J; Peng RS; Xu D; Li YH; Shi H; Wang Q; Yu J
    Drug Des Devel Ther; 2015; 9():5397-405. PubMed ID: 26451092
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A physiological approach for treating endometriosis by recombinant pigment epithelium-derived factor (PEDF).
    Chuderland D; Hasky N; Ben-Ami I; Kaplan-Kraicer R; Grossman H; Shalgi R
    Hum Reprod; 2013 Jun; 28(6):1626-34. PubMed ID: 23466670
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
    Chung TW; Kim SJ; Choi HJ; Kim KJ; Kim MJ; Kim SH; Lee HJ; Ko JH; Lee YC; Suzuki A; Kim CH
    Glycobiology; 2009 Mar; 19(3):229-39. PubMed ID: 18974200
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel anti-angiogenic therapeutic strategies in colorectal cancer.
    Tampellini M; Sonetto C; Scagliotti GV
    Expert Opin Investig Drugs; 2016; 25(5):507-20. PubMed ID: 26938715
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prodrug of green tea epigallocatechin-3-gallate (Pro-EGCG) as a potent anti-angiogenesis agent for endometriosis in mice.
    Wang CC; Xu H; Man GC; Zhang T; Chu KO; Chu CY; Cheng JT; Li G; He YX; Qin L; Lau TS; Kwong J; Chan TH
    Angiogenesis; 2013 Jan; 16(1):59-69. PubMed ID: 22948799
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions.
    Laschke MW; Elitzsch A; Vollmar B; Vajkoczy P; Menger MD
    Hum Reprod; 2006 Jan; 21(1):262-8. PubMed ID: 16172144
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs).
    Cosmai L; Gallieni M; Liguigli W; Porta C
    J Nephrol; 2017 Apr; 30(2):171-180. PubMed ID: 27154025
    [TBL] [Abstract][Full Text] [Related]  

  • 58. VEGF Expression in Pancreatic Cancer and Other Malignancies: A Review of the Literature.
    Costache MI; Ioana M; Iordache S; Ene D; Costache CA; Săftoiu A
    Rom J Intern Med; 2015; 53(3):199-208. PubMed ID: 26710495
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combined effect of vascular endothelial growth factor and its receptor polymorphisms in endometriosis: a case-control study.
    Cardoso JV; Abrão MS; Vianna-Jorge R; Ferrari R; Berardo PT; Machado DE; Perini JA
    Eur J Obstet Gynecol Reprod Biol; 2017 Feb; 209():25-33. PubMed ID: 27836223
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association between polymorphism rs11200638 in the HTRA1 gene and the response to anti-VEGF treatment of exudative AMD: a meta-analysis.
    Zhou YL; Chen CL; Wang YX; Tong Y; Fang XL; Li L; Wang ZY
    BMC Ophthalmol; 2017 Jun; 17(1):97. PubMed ID: 28637435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.